Advanced Search

Review Product Marketing Authorisation For Human Use «Rozex».

Original Language Title: Modifica dell'autorizzazione all'immissione in commercio delmedicinale per uso umano «Rozex».

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now for only USD$40 per month.
Retrieved March 4, 2015 # 386 of V determines & authorization of change: C.I. 4) one or more amendments to the summary of product characteristics, labelling and package leaflet after new data on quality, preclinical, clinical or pharmacovigilance medicine ROZEX;
Authorized updating of the summary of product characteristics in section 4.8 and corresponding paragraph leaflet and labels, relative to medicine ROZEX, shapes and packages listed below: AIC # 028809022-0.75% gel 30 g tube «» AIC # 028809034-' 1 ' 30 g tube cream 0.75% AIC # 028809059-0.75% 1 ' Skin Emulsion 30 g tube» handouts corrected and approved shall be annexed to the assessment under this extract.
Mah: Galderma Italy S.P.A. (tax 01539990349) with registered office and tax domicile in via dell'annunciata, 21, 20121-Milan (MI) Italy.
Printed 1. The marketing authorisation holder should make the changes, after the date of entry into force of this determination, the summary of product characteristics; no later than six months from the same date the package leaflet and labelling.
2. In accordance with art. 80, paragraphs 1 and 3, of Legislative Decree No 219 April 24, 2006 and s, leaflet and labels must be written in Italian and, limited to medicinal products marketed in the province of Bolzano, in German. The mAh avails itself of the complementary use of foreign languages, must give prior notice to the AIFA and keep available the certified translation of German texts and/or in another foreign language. In case of non-compliance with the provisions on the labelling and package leaflet shall apply sanctions under art. 82 of the aforementioned legislative decree.
Inventory disposal Both lots already products on the date of entry into force of this determination that the batches produced during the period referred to in article 2, paragraph 1, of the present, not bearing approved changes can be kept on the market until the expiration date printed on the label of the medicine. Pharmacists are required to deliver the package leaflet updated users, as from the end of 30 days from the date of publication in the Official Gazette of the Italian Republic of this determination. The Mah makes accessible to pharmacist leaflet updated within the same timeframe.
Date of determination: from the day following that of its publication, to decompress, in Gazzetta Ufficiale della Repubblica italiana.